Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:57 2025-12-05 EST			5-day change	1st Jan Change
107.08 ^CHF	+0.19%		+2.49%	+20.72%

12-05	Novartis raises guidance and target price after strong execution
12-04	Lupin Gets Tentative U.S. FDA Nod for Siponimod Tablets	MT

NOVARTIS AG : Berenberg reaffirms its Neutral rating

Published on 11/18/2025 at 02:38 am EST

MarketScreener with dpa-AFX Analyser

Novartis AG

+0.19%

Berenberg's research confirms his advice and maintains his neutral opinion on the stock. The target price has been revised upwards and is now set at CHF 92, compared with CHF 89 previously.

Latest news about Novartis AG

12-05	Novartis raises guidance and target price after strong execution
12-04	Lupin Gets Tentative U.S. FDA Nod for Siponimod Tablets	MT
12-03	Sector Update: Health Care Stocks Higher Late Afternoon	MT
12-03	Sector Update: Health Care	MT
12-03	Mizuho's Katz sees 'fertile' conditions driving robust M&A market into 2026	RE
12-03	Novartis Shares Rise After Morgan Stanley Upgrade	MT
12-03	Morgan Stanley Upgrades Novartis to Overweight From Equal Weight, $136 Price Target	MT
12-02	Tiziana Life Sciences to Set Up a Publicly Listed Immunology-Focused Spinout Company, Centered on the IL-6 Market	CI
12-02	Janux dives as gaps in prostate cancer study data worry investors	RE
12-02	Ovid Therapeutics Inc. Appoints Petra Kaufmann as Chief Medical Officer	CI
12-02	Tiziana Life Sciences Plans to Spin Out Asset as Separate Company	DJ
12-01	Novartis AG - Special Call
12-01	Whitehawk Therapeutics, Inc. Appoints Margaret Dugan as Chief Medical Officer	CI
11-25	US FDA approves Otsuka's drug for a type of kidney disease	RE
11-25	Swiss Market Index Closes Higher; Emmi, Novartis Shares Up	MT
11-25	Global markets live: Amazon, Alphabet, Boeing, Novartis, Novo Nordisk…
11-25	Sector Update: Health Care Stocks Edge Higher Premarket Tuesday	MT
11-25	Sector Update: Health Care	MT
11-25	Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Tuesday Ahead of Delayed Data Releases	MT
11-25	Novartis Gets FDA Approval for Spinal Muscular Atrophy Treatment; Shares Rise Premarket	MT
11-25	Novartis to Reshape Swiss Manufacturing with 550 Job Cuts at Stein Plant	MT
11-25	Novartis to Eliminate Up to 550 Roles at Stein Facility in Switzerland	MT
11-25	Novartis plans to cut up to 550 jobs at Swiss facility	RE
11-25	Novartis: Up to 550 jobs could go at Stein facility	RE
11-25	Novartis to present phase III trial for ianalumab in ITP	RE

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

05:15pm - American Society of Hematology Meeting - Abstract No - #724

More about the company